TY -的T1 -氯法齐明不会导致significant QT interval prolongation: a multicentre study JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01386-2018 VL - 52 IS - 5 SP - 1801386 AU - Zweijpfenning, Sanne M.H. AU - van Groningen, Hester AU - van Ingen, Jakko AU - Magis-Escurra, Cecile AU - Boeree, Martin J. AU - Wagner, Dirk AU - Bax, Hannelore AU - Andrejak, Claire AU - Wener, Reinier AU - Rahman, Ananna AU - Kunst, Heinke AU - Lorent, Natalie AU - Brouwer, Marc A. AU - Hoefsloot, Wouter A2 - , Y1 - 2018/11/01 UR - //www.qdcxjkg.com/content/52/5/1801386.abstract N2 - We read with great interest the article by Pontali et al. [1], entitled “Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence”. In response to this paper and the debate on potential QTc prolongation in clofazimine- and bedaquiline-containing multidrug-resistant tuberculosis (MDR-TB) treatment regimens [2, 3], we assessed QTc prolongation during clofazimine use in treatment of disease caused by nontuberculous mycobacteria (NTM). This is important as NTM disease treatment typically includes multiple potential QTc-prolonging antibiotics, including macrolides, fluoroquinolones and, increasingly, clofazimine [4].Clofazimine does not lead to significant QT interval prolongation in the treatment of nontuberculous mycobacteria http://ow.ly/sXC330lIbI8 ER -